Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukaemia
- Author
- LINDAUER, M1 ; DOMKIN, D1 ; FISCHER, T1 ; DÖHNER, H2 ; KOLB, H. J3 ; NEUBAUER, A4 ; HUHN, D5 ; KREITER, H6 ; KOCH, B7 ; HUBER, C1 ; AULITZKY, W8
[1] III. Medizinische Klinik, Universitätsklinikum, Mainz, Germany
[2] Medizinische Klinik V, Universitätsklinikum, Heidelberg, Germany
[3] Medizinische Klinik III, Ludwigs-Maximilians-Universität München (Klinikum Grosshadern), Berlin, Germany
[4] Abteilung für Hämatologie, Zentrum für Innere Medizin, Phillips Universität Marburg, Berlin, Germany
[5] Medizinische Klinik und Poliklinik, Universitätsklinikum Robert Virchow, Berlin, Germany
[6] Medizinische Klinik 1 Klinikum der Universitätsstadt Kaiserslautern, Stuttgart, Germany
[7] Innere Medizin 1, Universitätskliniken, Homburg/Saar, Germany
[8] Robert-Bosch Krankenhaus, Zentrum für Innere Medizin, Stuttgart, Germany - Source
British journal of haematology. 1999, Vol 106, Num 4, pp 1013-1019 ; ref : 1 p.1/4
- CODEN
- BJHEAL
- ISSN
- 0007-1048
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Association médicamenteuse Chimiothérapie Chronique Complication Cytarabine Efficacité traitement Homme Immunothérapie Leucopénie Leucémie myéloïde Pancytopénie Pronostic Pyrimidine nucléoside Thrombocyte Thrombopénie Toxicité Traitement associé Interféron alpha 2b Cytokine Hémopathie maligne Hémopathie Myéloprolifératif syndrome
- Keyword (en)
- Antineoplastic agent Drug combination Chemotherapy Chronic Complication Cytarabine Treatment efficiency Human Immunotherapy Leukopenia Chronic myelocytic leukemia Pancytopenia Prognosis Pyrimidine nucleoside Platelet Thrombocytopenia Toxicity Combined treatment Interferon alpha 2b Cytokine Malignant hemopathy Hemopathy Myeloproliferative syndrome
- Keyword (es)
- Anticanceroso Asociación medicamentosa Quimioterapia Crónico Complicación Citarabina Eficacia tratamiento Hombre Inmunoterapia Leucopenia Leucemia mieloidea Pancitopenia Pronóstico Pirimidina nucleósido Trombocito Trombopenia Toxicidad Tratamiento asociado Citoquina Hemopatía maligna Hemopatía Mieloproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R04 Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1946328
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1046/j.1365-2141.1999.01662.x 
https://dx.doi.org/10.1046/j.1365-2141.1999.01662.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1046\/j.1365-2141.1999.01662.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1019\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LINDAUER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"DOMKIN, D\";i:1;s:10:\"FISCHER, T\";i:2;s:10:\"D\u00d6HNER, H\";i:3;s:10:\"KOLB, H. J\";i:4;s:11:\"NEUBAUER, A\";i:5;s:7:\"HUHN, D\";i:6;s:10:\"KREITER, H\";i:7;s:7:\"KOCH, B\";i:8;s:8:\"HUBER, C\";i:9;s:11:\"AULITZKY, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1046\/j.1365-2141.1999.01662.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1019\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LINDAUER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"DOMKIN, D\";i:1;s:10:\"FISCHER, T\";i:2;s:10:\"D\u00d6HNER, H\";i:3;s:10:\"KOLB, H. J\";i:4;s:11:\"NEUBAUER, A\";i:5;s:7:\"HUHN, D\";i:6;s:10:\"KREITER, H\";i:7;s:7:\"KOCH, B\";i:8;s:8:\"HUBER, C\";i:9;s:11:\"AULITZKY, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1046\/j.1365-2141.1999.01662.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1046\/j.1365-2141.1999.01662.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1019\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LINDAUER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"DOMKIN, D\";i:1;s:10:\"FISCHER, T\";i:2;s:10:\"D\u00d6HNER, H\";i:3;s:10:\"KOLB, H. J\";i:4;s:11:\"NEUBAUER, A\";i:5;s:7:\"HUHN, D\";i:6;s:10:\"KREITER, H\";i:7;s:7:\"KOCH, B\";i:8;s:8:\"HUBER, C\";i:9;s:11:\"AULITZKY, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1046\/j.1365-2141.1999.01662.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1019\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LINDAUER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"DOMKIN, D\";i:1;s:10:\"FISCHER, T\";i:2;s:10:\"D\u00d6HNER, H\";i:3;s:10:\"KOLB, H. J\";i:4;s:11:\"NEUBAUER, A\";i:5;s:7:\"HUHN, D\";i:6;s:10:\"KREITER, H\";i:7;s:7:\"KOCH, B\";i:8;s:8:\"HUBER, C\";i:9;s:11:\"AULITZKY, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1046\/j.1365-2141.1999.01662.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:30:\"British journal of haematology\";s:9:\"\u0000*\u0000stitle\";s:15:\"Br. j. haematol\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:3:\"106\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1019\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-1048\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LINDAUER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:9:\"DOMKIN, D\";i:1;s:10:\"FISCHER, T\";i:2;s:10:\"D\u00d6HNER, H\";i:3;s:10:\"KOLB, H. J\";i:4;s:11:\"NEUBAUER, A\";i:5;s:7:\"HUHN, D\";i:6;s:10:\"KREITER, H\";i:7;s:7:\"KOCH, B\";i:8;s:8:\"HUBER, C\";i:9;s:11:\"AULITZKY, W\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJHEAL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"Efficacy and toxicity of IFN-\u03b12b combined with cytarabine in chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
